Success Metrics

Clinical Success Rate
79.6%

Based on 78 completed trials

Completion Rate
80%(78/98)
Active Trials
17(14%)
Results Posted
85%(66 trials)
Terminated
20(17%)

Phase Distribution

Ph phase_1
13
11%
Ph early_phase_1
1
1%
Ph phase_4
7
6%
Ph phase_3
21
17%
Ph phase_2
57
47%

Phase Distribution

14

Early Stage

57

Mid Stage

28

Late Stage

Phase Distribution99 total trials
Early Phase 1First-in-human
1(1.0%)
Phase 1Safety & dosage
13(13.1%)
Phase 2Efficacy & side effects
57(57.6%)
Phase 3Large-scale testing
21(21.2%)
Phase 4Post-market surveillance
7(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.8%

78 of 99 finished

Non-Completion Rate

21.2%

21 ended early

Currently Active

17

trials recruiting

Total Trials

121

all time

Status Distribution
Active(20)
Completed(78)
Terminated(21)
Other(2)

Detailed Status

Completed78
Terminated20
Active, not recruiting9
Recruiting8
Not yet recruiting2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
121
Active
17
Success Rate
79.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.0%)
Phase 113 (13.1%)
Phase 257 (57.6%)
Phase 321 (21.2%)
Phase 47 (7.1%)

Trials by Status

enrolling_by_invitation11%
withdrawn11%
not_yet_recruiting22%
active_not_recruiting97%
completed7864%
recruiting87%
terminated2017%
unknown22%

Recent Activity

Clinical Trials (121)

Showing 20 of 121 trialsScroll for more
NCT05090033

Characterizing the Use of Ofatumumab in a Real World Setting

Completed
NCT05344469

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Recruiting
NCT03488225Phase 2

Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

Terminated
NCT07625800

Switch to Ofatumumab and Level of Immunoglobulins

Not Yet Recruiting
NCT05809986

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

Recruiting
NCT06551519

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Active Not Recruiting
NCT06486779

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Recruiting
NCT06167642

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling By Invitation
NCT06867991Phase 3

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Recruiting
NCT05688436

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Active Not Recruiting
NCT05090371Phase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Active Not Recruiting
NCT05566756

Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

Completed
NCT03650114Phase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Active Not Recruiting
NCT02877303Phase 2

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

Recruiting
NCT04926818Phase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active Not Recruiting
NCT05171972

Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment

Completed
NCT06157086

Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

Active Not Recruiting
NCT07546110Early Phase 1

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

Not Yet Recruiting
NCT05285904

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

Completed
NCT06345157

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Active Not Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
121